The filed NT 10-Q reveals a very busy close of 2020. The activities Innovation Pharmaceuticals cite for the delay cause me to recalculate my estimates for PHII kick-off. Testing activity/prep, if not dosing, may have started earlier then originally thought. Can't wait for the shoe to drop. I hope IP includes detail in a 10-Q accompanying PR.